Jazz Pharmaceuticals PLC Company Profile (NASDAQ:JAZZ)

About Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Jazz Pharmaceuticals PLC logoJazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:JAZZ
  • CUSIP: G5087110
  • Web: www.jazzpharma.com
  • Market Cap: $8.44038 billion
  • Outstanding Shares: 60,064,000
Average Prices:
  • 50 Day Moving Avg: $147.87
  • 200 Day Moving Avg: $151.35
  • 52 Week Range: $95.80 - $163.75
  • Trailing P/E Ratio: 22.34
  • Foreward P/E Ratio: 12.87
  • P/E Growth: 0.74
Sales & Book Value:
  • Annual Revenue: $1.54 billion
  • Price / Sales: 5.66
  • Book Value: $36.64 per share
  • Price / Book: 3.96
  • EBITDA: $758.97 million
  • Net Margins: 25.69%
  • Return on Equity: 22.75%
  • Return on Assets: 9.14%
  • Debt-to-Equity Ratio: 0.74%
  • Current Ratio: 2.65%
  • Quick Ratio: 2.49%
  • Average Volume: 439,771 shs.
  • Beta: 1.05
  • Short Ratio: 4.84

Frequently Asked Questions for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

What is Jazz Pharmaceuticals PLC's stock symbol?

Jazz Pharmaceuticals PLC trades on the NASDAQ under the ticker symbol "JAZZ."

How were Jazz Pharmaceuticals PLC's earnings last quarter?

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) posted its quarterly earnings data on Tuesday, August, 8th. The company reported $1.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $1.85 by $0.13. The company had revenue of $394.39 million for the quarter, compared to analyst estimates of $410.83 million. Jazz Pharmaceuticals PLC had a return on equity of 22.75% and a net margin of 25.69%. Jazz Pharmaceuticals PLC's quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.67 EPS. View Jazz Pharmaceuticals PLC's Earnings History.

When will Jazz Pharmaceuticals PLC make its next earnings announcement?

Jazz Pharmaceuticals PLC is scheduled to release their next quarterly earnings announcement on Tuesday, November, 14th 2017. View Earnings Estimates for Jazz Pharmaceuticals PLC.

What guidance has Jazz Pharmaceuticals PLC issued on next quarter's earnings?

Jazz Pharmaceuticals PLC updated its FY17 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of $10.70-11.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $11.02. The company issued revenue guidance of $1.625-1.7 billion, compared to the consensus revenue estimate of $1.66 billion.

Where is Jazz Pharmaceuticals PLC's stock going? Where will Jazz Pharmaceuticals PLC's stock price be in 2017?

21 brokerages have issued 12 month price targets for Jazz Pharmaceuticals PLC's shares. Their predictions range from $144.00 to $210.00. On average, they expect Jazz Pharmaceuticals PLC's share price to reach $182.38 in the next year. View Analyst Ratings for Jazz Pharmaceuticals PLC.

What are analysts saying about Jazz Pharmaceuticals PLC stock?

Here are some recent quotes from research analysts about Jazz Pharmaceuticals PLC stock:

  • 1. According to Zacks Investment Research, "Jazz’s largest franchise is its sleep disorder portfolio. The company’s sleep disorder drug, Xyrem, is the only FDA-approved product for both cataplexy and EDS. Its lead pipeline candidate, JZP-110, being developed for the treatment of EDS in patients suffering from narcolepsy and OSA, complements its existing sleep disorder portfolio. Moreover, In Oct 2016, Jazz commenced a rolling submission for its second pipeline candidate, Vyxeos, which was completed in early Apr 2017. Jazz’ shares outperformed the industry so far this year. However, Xyrem is facing patent challenges. Jazz has also been facing challenges in building sufficient inventory levels for leukemia drug Erwinaze due to constrained manufacturing capacity and may experience further supply disruptions this year. Estimates have been stable lately ahead of the company’s Q2 earnings release." (8/8/2017)
  • 2. Cantor Fitzgerald analysts commented, "Meetings highlight view that late-stage assets are underappreciated. We hosted meetings with the CEO in the Midwest last week. Investors he met with expressed interest in Xyrem, of course, but the bulk of the questions centered around the pipeline. A common theme was that JZP-110 may be underestimated by the Street. We also spoke with some investors who seem to be gaining appreciation for the potential of the low-sodium oxybate formulations. Vyxeos approval could be around the corner. The PDUFA date for Vyxeos is September 30, and management commented that Breakthrough-designated drugs have been approved before the statutory date." (6/27/2017)
  • 3. Mizuho analysts commented, "We raise our PT to $162 from $152 while reiterating our Buy rating following positive Phase III data in a key pipeline drug (JZP-110) in obstructive sleep apnea. Our PT went up due to increased likelihood of FDA approval." (3/21/2017)
  • 4. Cowen and Company analysts commented, "complete re-rating."Cacciatore comments, "We continue to believe Jazz is nearing a very interesting inflection point, as a favorable resolution to the Xyrem litigation is likely, which could extend the franchise to 2024/2025. Combined with JZP-110's potential $750MM+ opportunity to complement growing Defitelio, Erwinaze, and ultimately Vyxeos, we believe a complete re-rating is nearing. We would add here." (3/20/2017)
  • 5. BMO Capital Markets analysts commented, "JAZZ delivered on an important milestone with positive Phase 3 data for JZP-110 in two OSA studies that appear to demonstrate a very solid clinical profile for this novel wake-promoting agent. There had been some concerns into these data (first OSA studies for JZP-110), and we think this outcome significantly de-risks the program; Phase 3 data in narcolepsy set for 2Q17 and filing in late 2017. We reiterate our Outperform; JAZZ remains a top pick." (3/20/2017)

Who are some of Jazz Pharmaceuticals PLC's key competitors?

Who owns Jazz Pharmaceuticals PLC stock?

Jazz Pharmaceuticals PLC's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Eqis Capital Management Inc. (0.01%). Company insiders that own Jazz Pharmaceuticals PLC stock include Bruce C Cozadd, Heather Ann Mcsharry, Karen J Wilson, Karen L Smith, Kenneth W O'keefe, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox, Seamus Mulligan and Suzanne Sawochka Hooper. View Institutional Ownership Trends for Jazz Pharmaceuticals PLC.

Who sold Jazz Pharmaceuticals PLC stock? Who is selling Jazz Pharmaceuticals PLC stock?

Jazz Pharmaceuticals PLC's stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. Company insiders that have sold Jazz Pharmaceuticals PLC stock in the last year include Bruce C Cozadd, Karen J Wilson, Michael Patrick Miller, Patrick G Enright, Paul L Berns, Paul Treacy, Rick E Winningham, Russell J Cox and Suzanne Sawochka Hooper. View Insider Buying and Selling for Jazz Pharmaceuticals PLC.

How do I buy Jazz Pharmaceuticals PLC stock?

Shares of Jazz Pharmaceuticals PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Jazz Pharmaceuticals PLC's stock price today?

One share of Jazz Pharmaceuticals PLC stock can currently be purchased for approximately $145.00.

MarketBeat Community Rating for Jazz Pharmaceuticals PLC (NASDAQ JAZZ)
Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  685 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  904
MarketBeat's community ratings are surveys of what our community members think about Jazz Pharmaceuticals PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Hold Ratings, 16 Buy Ratings
Consensus Rating:Buy (Score: 2.76)
Consensus Price Target: $182.38 (25.78% upside)
Consensus Price Target History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Price Target History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Analysts' Ratings History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/19/2017FBR & CoInitiated CoverageBuy -> Buy$206.00N/AView Rating Details
10/5/2017Morgan StanleyInitiated CoverageEqual -> Equal Weight$155.00N/AView Rating Details
9/28/2017Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral -> Neutral$165.00LowView Rating Details
9/20/2017BMO Capital MarketsReiterated RatingBuy$196.00HighView Rating Details
9/18/2017J P Morgan Chase & CoReiterated RatingBuy$190.00LowView Rating Details
9/15/2017Royal Bank Of CanadaReiterated RatingBuy$210.00LowView Rating Details
8/29/2017Cantor FitzgeraldReiterated RatingBuyLowView Rating Details
8/30/2017Stifel NicolausReiterated RatingBuy$190.00LowView Rating Details
8/29/2017Wells Fargo & CompanyReiterated RatingBuyLowView Rating Details
8/25/2017HC WainwrightInitiated CoverageNeutral -> Neutral$144.00LowView Rating Details
8/21/2017Cowen and CompanySet Price TargetBuy$190.00LowView Rating Details
8/10/2017Piper Jaffray CompaniesReiterated RatingBuy$177.00LowView Rating Details
8/9/2017Deutsche Bank AGSet Price TargetBuy$178.00 -> $175.00HighView Rating Details
8/9/2017Janney Montgomery ScottReiterated RatingBuy$180.00 -> $192.00LowView Rating Details
7/4/2017MizuhoDowngradeBuy -> Neutral$162.00 -> $150.00LowView Rating Details
7/4/2017Leerink SwannBoost Price TargetBuy$169.00 -> $170.00LowView Rating Details
5/22/2017Sanford C. BernsteinSet Price TargetMarket Perform$160.00 -> $176.00LowView Rating Details
2/22/2017Evercore ISIInitiated CoverageBuy$160.00N/AView Rating Details
2/16/2017GuggenheimReiterated RatingBuyN/AView Rating Details
1/19/2017SunTrust Banks, Inc.Reiterated RatingBuy$210.00N/AView Rating Details
1/18/2017Barclays PLCReiterated RatingOverweight$200.00N/AView Rating Details
4/5/2016Canaccord GenuityReiterated RatingBuy$170.00N/AView Rating Details
4/1/2016Northland SecuritiesReiterated RatingOutperform$175.00N/AView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Earnings by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Earnings History by Quarter for Jazz Pharmaceuticals PLC (NASDAQ JAZZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/20176/30/2017$1.85$1.72$410.83 million$394.39 millionViewListenView Earnings Details
5/9/20173/31/2017$1.42$1.41$376.58 million$376.10 millionViewListenView Earnings Details
2/28/2017Q416$2.65$1.91$398.91 million$396.62 millionViewListenView Earnings Details
11/8/2016Q316$2.61$2.16$389.34 million$374.00 millionViewListenView Earnings Details
8/9/2016Q216$2.80$2.63$376.40 million$381.00 millionViewN/AView Earnings Details
5/10/2016Q1$2.31$2.26$338.86 million$336.00 millionViewListenView Earnings Details
2/23/2016Q415$2.60$2.60$349.98 million$340.90 millionViewListenView Earnings Details
11/9/2015Q315$2.56$2.52$348.15 million$340.90 millionViewListenView Earnings Details
8/5/2015Q215$2.41$2.41$335.58 million$333.70 millionViewListenView Earnings Details
5/7/2015Q115$2.15$1.99$309.50 million$309.30 millionViewListenView Earnings Details
2/24/2015Q414$2.30$2.44$319.74 million$328.10 millionViewListenView Earnings Details
11/4/2014Q314$1.98$2.33$302.90 million$306.58 millionViewListenView Earnings Details
8/5/2014Q214$1.92$2.05$273.39 million$291.23 millionViewListenView Earnings Details
5/8/2014Q114$1.79$1.61$254.86 million$247.00 millionViewListenView Earnings Details
2/25/2014Q413$1.78$1.72$238.12 million$235.80 millionViewListenView Earnings Details
11/5/2013Q313$1.67$1.78$227.38 million$232.20 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.52$1.43$208.71 million$208.30 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.35$1.37$189.92 million$196.20 millionViewListenView Earnings Details
2/26/2013Q4 2012$1.41$1.53$183.80 million$183.70 millionViewListenView Earnings Details
11/8/2012Q312$1.31$1.29$178.57 million$175.50 millionViewN/AView Earnings Details
8/7/2012$1.05$1.09ViewN/AView Earnings Details
5/8/2012$0.90$0.91ViewN/AView Earnings Details
11/1/2011$0.89$0.94ViewN/AView Earnings Details
7/28/2011$0.67$0.82ViewN/AView Earnings Details
5/3/2011$0.57$0.59ViewN/AView Earnings Details
3/7/2011$0.60$0.63ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20172$1.89$2.84$2.37
Q3 20172$1.98$2.47$2.23
Q4 20172$2.77$2.78$2.78
(Data provided by Zacks Investment Research)


Dividend History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 87.82%
Insider Trades by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Institutional Ownership by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Insider Trades by Quarter for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/2/2017Bruce C CozaddCEOSell1,000$150.00$150,000.00View SEC Filing  
9/12/2017Bruce C. CozaddCEOSell1,000$153.52$153,520.00View SEC Filing  
8/25/2017Patrick G EnrightDirectorSell351$148.40$52,088.40View SEC Filing  
8/15/2017Michael Patrick MillerEVPSell200$144.38$28,876.00View SEC Filing  
8/14/2017Paul TreacySVPSell1,304$143.32$186,889.28View SEC Filing  
8/11/2017Paul L BernsDirectorSell662$142.37$94,248.94View SEC Filing  
7/20/2017Suzanne Sawochka HooperEVPSell4,580$160.00$732,800.00View SEC Filing  
7/17/2017Michael Patrick MillerEVPSell200$154.97$30,994.00View SEC Filing  
6/23/2017Suzanne Sawochka HooperEVPSell420$160.00$67,200.00View SEC Filing  
6/15/2017Michael Patrick MillerEVPSell200$150.65$30,130.00View SEC Filing  
6/1/2017Rick E WinninghamDirectorSell5,000$150.00$750,000.00View SEC Filing  
5/15/2017Michael Patrick MillerEVPSell200$152.98$30,596.00View SEC Filing  
5/11/2017Bruce C CozaddCEOSell30,000$153.47$4,604,100.00View SEC Filing  
5/9/2017Suzanne Sawochka HooperEVPSell2,500$160.00$400,000.00View SEC Filing  
4/27/2017Karen J WilsonSVPSell1,275$160.00$204,000.00View SEC Filing  
4/27/2017Suzanne Sawochka HooperEVPSell2,500$160.00$400,000.00View SEC Filing  
4/17/2017Michael Patrick MillerSVPSell200$152.56$30,512.00View SEC Filing  
4/11/2017Bruce C CozaddCEOSell1,000$152.12$152,120.00View SEC Filing  
4/10/2017Karen J WilsonSVPSell11,458$152.24$1,744,365.92View SEC Filing  
3/15/2017Michael Patrick MillerSVPSell200$137.89$27,578.00View SEC Filing  
3/6/2017Paul TreacySVPSell884$131.97$116,661.48View SEC Filing  
2/15/2017Michael Patrick MillerSVPSell200$134.55$26,910.00View SEC Filing  
1/18/2017Russell J. CoxCOOSell4,000$128.75$515,000.00View SEC Filing  
1/17/2017Michael Patrick MillerSVPSell200$115.93$23,186.00View SEC Filing  
12/15/2016Michael Patrick MillerSVPSell200$103.09$20,618.00View SEC Filing  
12/2/2016Patrick G EnrightDirectorSell677$101.80$68,918.60View SEC Filing  
11/15/2016Michael Patrick MillerSVPSell200$112.19$22,438.00View SEC Filing  
11/14/2016Kenneth W O'keefeDirectorBuy2,000$113.84$227,680.00View SEC Filing  
10/17/2016Michael Patrick MillerSVPSell200$118.16$23,632.00View SEC Filing  
9/19/2016Michael Patrick MillerSVPSell200$126.17$25,234.00View SEC Filing  
8/25/2016Seamus MulliganDirectorSell27,968$128.32$3,588,853.76View SEC Filing  
8/16/2016Paul TreacySVPSell1,292$137.47$177,611.24View SEC Filing  
8/15/2016Michael Patrick MillerSVPSell100$136.45$13,645.00View SEC Filing  
8/15/2016Rick E WinninghamDirectorSell633$136.45$86,372.85View SEC Filing  
8/12/2016Karen L SmithInsiderBuy608$137.10$83,356.80View SEC Filing  
8/9/2016Bruce C. CozaddCEOSell1,000$150.00$150,000.00View SEC Filing  
8/9/2016Russell J. CoxCOOSell4,000$148.66$594,640.00View SEC Filing  
7/15/2016Michael Patrick MillerSVPSell100$142.43$14,243.00View SEC Filing  
7/13/2016Karen L SmithCMOBuy580$143.63$83,305.40View SEC Filing  
6/15/2016Michael Patrick MillerSVPSell100$149.64$14,964.00View SEC Filing  
6/13/2016Karen L SmithCMOBuy557$149.61$83,332.77View SEC Filing  
5/16/2016Heather Ann McsharryDirectorSell697$145.20$101,204.40View SEC Filing  
5/16/2016Michael Patrick MillerSVPSell100$145.20$14,520.00View SEC Filing  
4/25/2016Karen J WilsonSVPSell604$160.00$96,640.00View SEC Filing  
4/15/2016Michael Patrick MillerSVPSell100$145.79$14,579.00View SEC Filing  
4/13/2016Karen J WilsonSVPSell5,007$150.00$751,050.00View SEC Filing  
4/12/2016Russell J CoxCOOSell4,000$136.98$547,920.00View SEC Filing  
4/7/2016Karen J WilsonSVPSell2,161$140.90$304,484.90View SEC Filing  
3/15/2016Michael Patrick MillerSVPSell100$129.17$12,917.00View SEC Filing  
3/8/2016Bruce C CozaddCEOSell2,500$126.04$315,100.00View SEC Filing  
2/29/2016Paul TreacySVPSell354$123.48$43,711.92View SEC Filing  
2/23/2016Seamus MulliganDirectorSell27,968$122.71$3,431,953.28View SEC Filing  
2/16/2016Michael Patrick MillerSVPSell100$115.63$11,563.00View SEC Filing  
2/10/2016Patrick G EnrightDirectorSell10,000$117.92$1,179,200.00View SEC Filing  
2/9/2016Bruce C CozaddCEOSell2,500$111.37$278,425.00View SEC Filing  
1/15/2016Michael Patrick MillerSVPSell100$122.66$12,266.00View SEC Filing  
1/12/2016Bruce C CozaddCEOSell2,500$123.81$309,525.00View SEC Filing  
1/5/2016Patrick G EnrightDirectorSell10,000$138.09$1,380,900.00View SEC Filing  
12/15/2015Michael Patrick MillerSVPSell100$136.99$13,699.00View SEC Filing  
12/8/2015Bruce C CozaddCEOSell2,500$139.72$349,300.00View SEC Filing  
12/2/2015Patrick G EnrightDirectorSell10,424$146.67$1,528,888.08View SEC Filing  
11/23/2015Seamus MulliganDirectorSell27,968$145.86$4,079,412.48View SEC Filing  
11/10/2015Bruce C CozaddCEOSell2,500$128.53$321,325.00View SEC Filing  
11/10/2015Patrick G EnrightDirectorSell10,000$135.29$1,352,900.00View SEC Filing  
10/21/2015Suzanne Sawochka HooperEVPSell2,000$125.00$250,000.00View SEC Filing  
10/13/2015Bruce C CozaddCEOSell2,500$131.50$328,750.00View SEC Filing  
10/5/2015Patrick G EnrightDirectorSell10,000$133.79$1,337,900.00View SEC Filing  
9/25/2015Michael Patrick MillerSVPSell100$145.23$14,523.00View SEC Filing  
9/8/2015Bruce C. CozaddCEOSell2,500$163.07$407,675.00View SEC Filing  
9/1/2015Patrick G EnrightDirectorSell10,000$165.99$1,659,900.00View SEC Filing  
7/14/2015Bruce C CozaddCEOSell5,000$177.79$888,950.00View SEC Filing  
7/14/2015Suzanne Sawochka HooperEVPSell4,000$177.79$711,160.00View SEC Filing  
7/6/2015Patrick G EnrightDirectorSell10,000$177.11$1,771,100.00View SEC Filing  
6/9/2015Bruce C CozaddCEOSell5,000$173.16$865,800.00View SEC Filing  
6/9/2015Suzanne Sawochka HooperEVPSell4,000$173.16$692,640.00View SEC Filing  
6/2/2015Karen J WilsonSVPSell5,751$179.59$1,032,822.09View SEC Filing  
6/1/2015Karen J WilsonSVPSell5,494$179.57$986,557.58View SEC Filing  
4/14/2015Bruce C CozaddCEOSell5,000$181.45$907,250.00View SEC Filing  
4/14/2015Suzanne Sawochka HooperEVPSell4,000$181.45$725,800.00View SEC Filing  
3/25/2015Seamus MulliganDirectorSell50,000$174.59$8,729,500.00View SEC Filing  
1/5/2015Patrick G EnrightDirectorSell10,000$160.25$1,602,500.00View SEC Filing  
12/26/2014Seamus MulliganDirectorSell50,000$163.40$8,170,000.00View SEC Filing  
12/12/2014Patrick G EnrightDirectorSell2,343$170.98$400,606.14View SEC Filing  
12/9/2014Bruce C CozaddCEOSell5,000$178.79$893,950.00View SEC Filing  
12/9/2014Suzanne Sawochka HooperEVPSell1,852$178.79$331,119.08View SEC Filing  
12/1/2014Patrick G EnrightDirectorSell10,000$172.74$1,727,400.00View SEC Filing  
11/24/2014Jeffrey K TobiasCMOSell4,598$170.12$782,211.76View SEC Filing  
11/7/2014Iain McgillSVPSell7,066$172.03$1,215,563.98View SEC Filing  
10/10/2014Jeffrey K TobiasCMOSell1,000$154.04$154,040.00View SEC Filing  
10/6/2014Patrick G EnrightDirectorSell10,000$160.56$1,605,600.00View SEC Filing  
9/25/2014Seamus MulliganDirectorSell50,000$163.16$8,158,000.00View SEC Filing  
9/24/2014Seamus MulliganDirectorSell35,294$163.70$5,777,627.80View SEC Filing  
9/12/2014Jeffrey K TobiasCMOSell1,000$171.22$171,220.00View SEC Filing  
9/11/2014Karen J WilsonSVPSell3,000$175.00$525,000.00View SEC Filing  
9/11/2014Seamus MulliganDirectorSell50,000$175.00$8,750,000.00View SEC Filing  
9/9/2014Bruce C CozaddCEOSell5,000$170.32$851,600.00View SEC Filing  
9/8/2014Karen J WilsonSVPSell2,500$170.00$425,000.00View SEC Filing  
9/8/2014Suzanne Sawochka HooperEVPSell1,852$168.00$311,136.00View SEC Filing  
8/12/2014Bruce C CozaddCEOSell5,000$133.15$665,750.00View SEC Filing  
8/12/2014Suzanne Sawochka HooperEVPSell1,185$133.15$157,782.75View SEC Filing  
8/11/2014Jeffrey K TobiasCMOSell4,933$135.42$668,026.86View SEC Filing  
7/8/2014Bruce C CozaddCEOSell5,000$155.00$775,000.00View SEC Filing  
7/8/2014Suzanne Sawochka HooperEVPSell1,853$155.00$287,215.00View SEC Filing  
7/7/2014Karen J WilsonSVPSell2,500$165.00$412,500.00View SEC Filing  
6/25/2014Seamus MulliganDirectorSell50,000$149.69$7,484,500.00View SEC Filing  
6/20/2014Russell J CoxCOOSell2,000$155.00$310,000.00View SEC Filing  
6/17/2014Fintan KeeganEVPSell3,750$150.00$562,500.00View SEC Filing  
6/10/2014Bruce C CozaddCEOSell5,000$142.34$711,700.00View SEC Filing  
5/16/2014Jeffrey TobiasCMOSell1,000$128.01$128,010.00View SEC Filing  
5/13/2014Bruce CozaddCEOSell5,000$128.92$644,600.00View SEC Filing  
4/17/2014Rick WinninghamDirectorSell27,500$140.00$3,850,000.00View SEC Filing  
4/14/2014Jeffrey TobiasCMOSell3,000$128.54$385,620.00View SEC Filing  
4/8/2014Bruce CozaddCEOSell5,000$123.18$615,900.00View SEC Filing  
3/10/2014Jeffrey TobiasCMOSell3,000$152.99$458,970.00View SEC Filing  
3/6/2014Fintan KeeganEVPSell4,640$159.90$741,936.00View SEC Filing  
3/4/2014Seamus MulliganDirectorSell550,000$156.25$85,937,500.00View SEC Filing  
3/3/2014Patrick EnrightDirectorSell559,628$152.39$85,281,710.92View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
Latest Headlines for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)
benzinga.com logoBenzinga's Top Upgrades, Downgrades For October 19, 2017 - Benzinga
www.benzinga.com - October 20 at 1:23 AM
nasdaq.com logoImmunoGen to Push Leukemia Candidate into Phase I Trial - Nasdaq - Nasdaq
www.nasdaq.com - October 18 at 5:02 PM
americanbankingnews.com logoZacks: Analysts Anticipate Jazz Pharmaceuticals PLC (JAZZ) Will Announce Quarterly Sales of $420.76 Million
www.americanbankingnews.com - October 17 at 9:52 AM
americanbankingnews.com logoContrasting Aevi Genomic Medicine (GNMX) and Jazz Pharmaceuticals PLC (JAZZ)
www.americanbankingnews.com - October 16 at 6:28 PM
americanbankingnews.com logo Brokerages Anticipate Jazz Pharmaceuticals PLC (JAZZ) to Post $2.88 EPS
www.americanbankingnews.com - October 15 at 6:24 AM
seekingalpha.com logoJazz Pharmaceuticals Struggles With Sluggish Sales, High Stock Price
seekingalpha.com - October 13 at 7:59 PM
finance.yahoo.com logoETFs with exposure to Jazz Pharmaceuticals Plc : October 11, 2017
finance.yahoo.com - October 11 at 4:50 PM
nasdaq.com logoNotable Two Hundred Day Moving Average Cross - JAZZ - Nasdaq
www.nasdaq.com - October 10 at 7:30 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) & Senesco Technologies (SVON) Head to Head Analysis
www.americanbankingnews.com - October 9 at 12:40 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) & Its Rivals Head to Head Comparison
www.americanbankingnews.com - October 6 at 8:30 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) versus Mateon Therapeutics (MATN) Financial Comparison
www.americanbankingnews.com - October 6 at 4:28 AM
americanbankingnews.com logoMorgan Stanley Begins Coverage on Jazz Pharmaceuticals PLC (JAZZ)
www.americanbankingnews.com - October 5 at 8:18 PM
finance.yahoo.com logoJazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : October 3, 2017
finance.yahoo.com - October 5 at 5:10 AM
americanbankingnews.com logoBruce C. Cozadd Sells 1,000 Shares of Jazz Pharmaceuticals PLC (JAZZ) Stock
www.americanbankingnews.com - October 4 at 8:28 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - October 1 at 10:46 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Research Coverage Started at Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - September 28 at 6:20 PM
americanbankingnews.com logo$419.60 Million in Sales Expected for Jazz Pharmaceuticals PLC (JAZZ) This Quarter
www.americanbankingnews.com - September 28 at 5:36 AM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Expected to Announce Earnings of $2.88 Per Share
www.americanbankingnews.com - September 26 at 12:28 PM
finance.yahoo.com logoETFs with exposure to Jazz Pharmaceuticals Plc : September 25, 2017
finance.yahoo.com - September 25 at 6:37 PM
americanbankingnews.com logoFinancial Contrast: Jazz Pharmaceuticals PLC (JAZZ) and Ohr Pharmaceuticals (OHRP)
www.americanbankingnews.com - September 25 at 2:18 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Price Target Lowered to $172.00 at UBS AG
www.americanbankingnews.com - September 25 at 12:52 PM
americanbankingnews.com logoComparing Jazz Pharmaceuticals PLC (JAZZ) and Its Competitors
www.americanbankingnews.com - September 24 at 10:20 AM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Rating Reiterated by BMO Capital Markets
www.americanbankingnews.com - September 24 at 12:16 AM
americanbankingnews.com logoAnalyzing Jazz Pharmaceuticals PLC (JAZZ) & Its Peers
www.americanbankingnews.com - September 21 at 2:30 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Rating Reiterated by J P Morgan Chase & Co
www.americanbankingnews.com - September 18 at 9:34 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) vs. Its Rivals Critical Survey
www.americanbankingnews.com - September 17 at 10:16 AM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) versus Its Rivals Critical Survey
www.americanbankingnews.com - September 17 at 12:32 AM
americanbankingnews.com logoShort Interest in Jazz Pharmaceuticals PLC (JAZZ) Rises By 39.2%
www.americanbankingnews.com - September 16 at 1:44 AM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Stock Rating Reaffirmed by Royal Bank Of Canada
www.americanbankingnews.com - September 15 at 9:15 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) and Its Competitors Critical Review
www.americanbankingnews.com - September 15 at 12:34 PM
finance.yahoo.com logoETFs with exposure to Jazz Pharmaceuticals Plc : September 14, 2017
finance.yahoo.com - September 15 at 2:33 AM
finance.yahoo.com logoJazz Pharmaceuticals Plc :JAZZ-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
finance.yahoo.com - September 14 at 6:43 AM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) CEO Bruce C. Cozadd Sells 1,000 Shares
www.americanbankingnews.com - September 13 at 8:28 PM
finance.yahoo.com logoJazz Pharmaceuticals Plc – Value Analysis (NASDAQ:JAZZ) : September 12, 2017
finance.yahoo.com - September 12 at 10:00 PM
prnewswire.com logoFortune Magazine Names Jazz Pharmaceuticals 78th Fastest Growing Company for 2017 - PR Newswire (press release)
www.prnewswire.com - September 12 at 4:58 PM
finance.yahoo.com logoFortune Magazine Names Jazz Pharmaceuticals 78th Fastest Growing Company for 2017
finance.yahoo.com - September 12 at 4:58 PM
finance.yahoo.com logoWhere Jazz Pharmaceuticals’ Erwinaze and Prialt Are Positioned after 2Q17
finance.yahoo.com - September 11 at 9:06 PM
finance.yahoo.com logoJazz Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : JAZZ-US : September 11, 2017
finance.yahoo.com - September 11 at 9:06 PM
americanbankingnews.com logo$420.74 Million in Sales Expected for Jazz Pharmaceuticals PLC (JAZZ) This Quarter
www.americanbankingnews.com - September 9 at 1:48 AM
finance.yahoo.com logoWhy Jazz Pharmaceuticals’ Vyxeos Could Boost Revenue Growth in 2018
finance.yahoo.com - September 9 at 1:41 AM
finance.yahoo.com logoThis Could Drive Jazz Pharmaceuticals’ Revenue Growth
finance.yahoo.com - September 9 at 1:41 AM
finance.yahoo.com logoHow Is Jazz’s Defitelio Positioned after 2Q17?
finance.yahoo.com - September 9 at 1:40 AM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Expected to Post Earnings of $2.89 Per Share
www.americanbankingnews.com - September 7 at 10:24 PM
finance.yahoo.com logoHow Did Jazz Pharmaceuticals Perform in 1H17?
finance.yahoo.com - September 7 at 9:02 PM
americanbankingnews.com logoJazz Pharmaceuticals PLC (JAZZ) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - September 6 at 10:42 PM
finance.yahoo.com logoBull of the Day: Jazz Pharmaceuticals (JAZZ)
finance.yahoo.com - September 5 at 4:52 PM
finance.yahoo.com logoJazz Pharmaceuticals Announces Completion of Offering and Exercise in Full of Initial Purchasers' Option to Purchase Additional 1.50% Exchangeable Senior Notes due 2024
finance.yahoo.com - September 2 at 1:35 AM
americanbankingnews.com logoSunTrust Banks Comments on Jazz Pharmaceuticals PLC's FY2017 Earnings (JAZZ)
www.americanbankingnews.com - September 1 at 7:42 AM
marketwatch.com logoFormer Celator Pharmaceuticals accountant, three others charged with insider trading - MarketWatch
www.marketwatch.com - September 1 at 1:14 AM
prnewswire.com logoJazz Pharmaceuticals to Present at the Wells Fargo Securities Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - September 1 at 1:14 AM



Jazz Pharmaceuticals PLC (JAZZ) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.